Vanessa El Kamari1,2, Carlee Moser3, Corrilynn O Hileman1,4, Judith S Currier5, Todd T Brown6, Liz Johnston3, Peter W Hunt7, Grace A McComsey1,2. 1. Case Western Reserve University, Ohio. 2. University Hospitals Cleveland Medical Center, Ohio. 3. Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 4. MetroHealth Medical Center, Cleveland, Ohio. 5. University of California Los Angeles. 6. Johns Hopkins, Baltimore, Maryland. 7. University of California San Francisco.
Abstract
BACKGROUND: Fat accumulation and insulin resistance remain a threat to the success of antiretroviral therapy (ART). The role of gut dysfunction in metabolic complications associated with ART initiation is unclear. METHODS:Human immunodeficiency virus (HIV)-infected ART-naive participants were randomized to tenofovir disoproxil fumarate/emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir, or raltegravir (RAL). Changes in the gut integrity markers zonulin, lipopolysaccharide-binding protein (LBP), and intestinal fatty acid and ileal bile acid binding proteins (I-FABP and I-BABP) were assessed over 96 weeks. Wilcoxon rank-sum tests were used to compare changes between groups and linear regression models to quantify associations between gut markers, insulin resistance, body mass index (BMI), and visceral, subcutaneous, and total adipose tissue (VAT, SAT, and TAT). RESULTS: : 90% were male and 48% were White non-Hispanic. The median age was 36 years, HIV-1 ribonucleic acid was 4.56 log10 copies/mL, and CD4 count was 338 cells/µL. An overall 1.7-fold increase in I-FABP was observed throughout 96 weeks, with no difference between arms. Zonulin levels increased with RAL compared to protease inhibitor-based regimens (week 96, P = .02); minimal changes in I-BABP or LBP levels were observed. Higher baseline I-FABP levels were associated with increases in VAT, TAT, and BMI (16%, 9%, and 2.5%, respectively; P < .04) over 96 weeks. CONCLUSIONS: While ART induces changes in the markers of gut barrier dysfunction, the extent to which they improve or worsen the gut barrier function remains unclear. Nevertheless, markers of gut barrier dysfunction in ART-naive individuals predict increases in total and visceral abdominal fat with treatment initiation.
RCT Entities:
BACKGROUND: Fat accumulation and insulin resistance remain a threat to the success of antiretroviral therapy (ART). The role of gut dysfunction in metabolic complications associated with ART initiation is unclear. METHODS: Human immunodeficiency virus (HIV)-infected ART-naive participants were randomized to tenofovir disoproxil fumarate/emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir, or raltegravir (RAL). Changes in the gut integrity markers zonulin, lipopolysaccharide-binding protein (LBP), and intestinal fatty acid and ileal bile acid binding proteins (I-FABP and I-BABP) were assessed over 96 weeks. Wilcoxon rank-sum tests were used to compare changes between groups and linear regression models to quantify associations between gut markers, insulin resistance, body mass index (BMI), and visceral, subcutaneous, and total adipose tissue (VAT, SAT, and TAT). RESULTS: : 90% were male and 48% were White non-Hispanic. The median age was 36 years, HIV-1 ribonucleic acid was 4.56 log10 copies/mL, and CD4 count was 338 cells/µL. An overall 1.7-fold increase in I-FABP was observed throughout 96 weeks, with no difference between arms. Zonulin levels increased with RAL compared to protease inhibitor-based regimens (week 96, P = .02); minimal changes in I-BABP or LBP levels were observed. Higher baseline I-FABP levels were associated with increases in VAT, TAT, and BMI (16%, 9%, and 2.5%, respectively; P < .04) over 96 weeks. CONCLUSIONS: While ART induces changes in the markers of gut barrier dysfunction, the extent to which they improve or worsen the gut barrier function remains unclear. Nevertheless, markers of gut barrier dysfunction in ART-naive individuals predict increases in total and visceral abdominal fat with treatment initiation.
Authors: Irini Sereti; Shelly J Krebs; Nittaya Phanuphak; James L Fletcher; Bonnie Slike; Suteeraporn Pinyakorn; Robert J O'Connell; Adam Rupert; Nicolas Chomont; Victor Valcour; Jerome H Kim; Merlin L Robb; Nelson L Michael; Daniel C Douek; Jintanat Ananworanich; Netanya S Utay Journal: Clin Infect Dis Date: 2016-10-12 Impact factor: 9.079
Authors: Aisha Nazli; Olivia Chan; Wendy N Dobson-Belaire; Michel Ouellet; Michel J Tremblay; Scott D Gray-Owen; A Larry Arsenault; Charu Kaushic Journal: PLoS Pathog Date: 2010-04-08 Impact factor: 6.823
Authors: Maurice M A L Pelsers; Zbigniew Namiot; Wojciech Kisielewski; Andrzej Namiot; Marcin Januszkiewicz; Wim T Hermens; Jan F C Glatz Journal: Clin Biochem Date: 2003-10 Impact factor: 3.281
Authors: Sahera Dirajlal-Fargo; Carlee Moser; Todd T Brown; Theodoros Kelesidis; Michael P Dube; James H Stein; Judith Currier; Grace A McComsey Journal: Open Forum Infect Dis Date: 2016-08-29 Impact factor: 3.835
Authors: S Dirajlal-Fargo; L Shan; A Sattar; E Bowman; J Gabriel; M Kulkarni; N Funderburg; R Nazzinda; V Musiime; G A McComsey Journal: HIV Med Date: 2019-10-23 Impact factor: 3.180